Evidence map›Paper›PMID 38271588›Full record

ArticleACS chemical biology2024

A Tandem-Affinity Purification Method for Identification of Primary Intracellular Drug-Binding Proteins.

Sehbanul Islam, Jitendra Gour, Thomas Beer, Hsin-Yao Tang, Joel Cassel, Joseph M Salvino, Luca Busino

Open access · greenAbstract read
In one paragraph

Article in ACS chemical biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Editorial: Emerging mechanisms of host-pathogen interactions and immune responses.Frontiers in cellular and infection microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sehbanul IslamUniversity of Pennsylvania, Perelman School of Medicine, Department of Cancer Biology, Philadelphia, Pennsylvania 19104, United States.
Jitendra GourMedicinal Chemistry and Molecular and Cellular Oncogenesis (MCO) Program, The Wistar Institute, Philadelphia, Pennsylvania 19104, United States.
Thomas BeerMedicinal Chemistry and Molecular and Cellular Oncogenesis (MCO) Program, The Wistar Institute, Philadelphia, Pennsylvania 19104, United States.
Hsin-Yao TangMedicinal Chemistry and Molecular and Cellular Oncogenesis (MCO) Program, The Wistar Institute, Philadelphia, Pennsylvania 19104, United States.
Joel CasselMolecular Screening and Protein Expression Shared Resource, The Wistar Institute, Philadelphia, Pennsylvania 19104, United States.
Joseph M SalvinoMedicinal Chemistry and Molecular and Cellular Oncogenesis (MCO) Program, The Wistar Institute, Philadelphia, Pennsylvania 19104, United States.ORCID 0000-0002-2184-5980
Luca BusinoUniversity of Pennsylvania, Perelman School of Medicine, Department of Cancer Biology, Philadelphia, Pennsylvania 19104, United States.ORCID 0000-0001-6758-9276
The Wistar Institute · USUniversity of Pennsylvania · US

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9M
Targeting the Epigenetic and Metabolic Control of EBV-Epithelial CancersP01CA269043 · NCI · WISTAR INSTITUTE · PI Italo Tempera · 2023 to 2026
$12.0M
Role of KLHL6 inactivation in mature B-cell malignanciesR01CA207513 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Luca Busino · 2016 to 2026
$4.2M
Regulation of emergency hematopoiesis by the ubiquitin-proteasome systemR01HL159175 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI AIFANTIS, IANNIS, BUSINO, LUCA · 2021 to 2024
$2.5M
Advancing Cancer Research through Comprehensive Proteomics and Metabolomics AnalysesR50CA221838 · NCI · WISTAR INSTITUTE · PI Hsin-Yao Tang · 2017 to 2026
$2.1M
Purchase of an Echo 650 acoustic liquid handler with Access workstationS10OD030245 · OD · WISTAR INSTITUTE · PI SALVINO, JOSEPH M · 2021 to 2021
$567k
NCI NIH HHS P01 CA269043NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA207513NCI NIH HHS R50 CA221838NHLBI NIH HHS R01 HL159175NIH HHS S10 OD030245
6 · The paper itself

Abstract

In the field of drug discovery, understanding how small molecule drugs interact with cellular components is crucial. Our study introduces a novel methodology to uncover primary drug targets using

Indexed as

Carrier ProteinsTandem Affinity PurificationChromatography, AffinityProteinsTacrolimus Binding Protein 1ACarrier ProteinsProteinsTacrolimus Binding Protein 1A

Identifiers

PMID38271588
PMCPMC10878392
OpenAlexW4391214888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.